Evoke Pharma Inc., of Solana Beach, Calif., said it expects to provide top-line results from its pivotal phase III trial of EVK-001 in women with symptoms associated with diabetic gastroparesis early in the third quarter. The company confirmed that 205 subjects have been randomized in the trial testing the nasal delivery formulation of metoclopramide.